Navigation Links
Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
Date:12/6/2008

- Results Presented at ASH Annual Meeting-

SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid (PUA) levels compared to allopurinol alone (p=0.0012). The study also compared a sequential combination of the two agents (Elitek for three days followed by allopurinol for three days, with one day overlap) versus allopurinol alone, which showed a reduction in plasma uric acid levels for the sequential combination versus allopurinol alone (p=0.06).

Tumor lysis syndrome is a potentially life-threatening metabolic complication that can result either spontaneously or following treatment of certain types of rapid-growing cancers, particularly leukemia or lymphoma. The syndrome develops when a particularly large volume of cells associated with fast growing tumors are destroyed, releasing cellular by-products into the blood system such as uric acid, faster than can be eliminated. Elevated levels of plasma uric acid can cause hyperuricemia, a serious condition that can lead to renal failure if not controlled.

The primary objective of the multi-center, open-label, randomized, parallel group comparative study was to compare the adequacy of control of PUA concentration and the safety profile in three treatment arms. Among the three treatment arms, plasma uric acid response rate (defined as normalization or maintenance of PUA levels less than or equal to 7.5mg/dl at days 3-7) was 87% of patients treated with Elitek compared to 66% receiving allopurinol alone (p=0.001) and 78% with Elitek/allopurinol (p=0.06). Among patients at high risk for tumor lysis syndrome, the PUA response rate was 89% with Elitek vs. 68% with allopurinol and 79% with the Elitek/allopurinol combination (p=0.0012). The PUA response rate among patients with baseline hyperuricemia defined as plasma uric acid >7.5mg/dL was 90% with Elitek versus 53% with allopurinol and 77% with Elitek/allopurinol (p=0.0151). The time to control, or normalize, PUA in hyperuricemic patients was 4.1 hours among patients treated with Elitek (n=18 [95% CI=4.0 to 4.5]), 4.1 hours with the Elitek/allopurinol combination (n=12 [95% CI=3.9 to 4.5) and 27.0 hours in the allopurinol alone arm (n=17 [95% CI=4.0 to 49.0]).

"In this investigational study, Elitek controlled plasma uric acid in a larger percentage of patients and in a shorter period of time than allopurinol, the current U.S. standard treatment in adults," said principal investigator Dr. Jorge Cortes, Professor of Medicine and Deputy Chair, Department of Leukemia at The University of Texas, MD Anderson Cancer Center, in Houston, Texas.

In both Elitek groups, there was a 2% incidence of Grade 3/4 related events and <5% hypersensitivity or immuno-allergic reactions, 1% of which were Grade 3 or higher. The most common serious adverse reactions regardless of the relationship to the study drug were neutropenic sepsis (5.4% / 1.1% / 3.3%), neutropenic infection (5.4% / 4.3% / 8.8%), and febrile neutropenia (4.3% / 3.3% / 5.5%), pulmonary hemorrhage (1.1% / 3.3% / 0%), and respiratory failure (2.2% / 3.3% / 1.1%) in the Elitek, Elitek/allopurinol and allopurinol arms, respectively. Elitek treatment-related events were considered rarely serious, and less than or equal to 1% led to discontinuation of treatment. Investigators reported that there were no major differences in safety or tolerability between the three treatment arms, and that most adverse events were related to chemotherapy and/or the underlying disease.

These study results will form the basis for a supplemental new drug application submission to the U.S. Food and Drug Administration.

Background on Study Design

Patients received Elitek at a dosage of 0.20 mg/kg/day for five days (n=92), Elitek at the same dosage for three days plus allopurinol (300 mg/day) starting on the third day and continuing for another two days (n=92), or allopurinol (300 mg/day) for five days (n=91). Secondary objectives of the study were to evaluate among the three treatment arms the AUC (area under the curve) of plasma uric acid from baseline through 48 hours after the last planned anti-hyperuricemic treatment, the time to plasma uric acid control, safety (including immunogenicity) and pharmacokinetics.

Patients eligible to enter the study were at least 18 years old with Eastern Cooperative Oncology Group (ECOG) performance 0-3, a life expectancy of greater than three months and at either high or potential risk for TLS: High risk for TLS was defined as hyperuricemia from the cancer at baseline (plasma uric acid >7.5 mg/dL), very aggressive lymphoma/leukemia as defined by the Revised European-American Lymphoma (REAL) criteria, acute myeloid leukemia (AML), chronic myeloid leukemia (CML) in blast crisis, or high grade myelodysplastic syndrome (MDS) with >10% bone marrow involvement. Potential risk for TLS was defined as diagnosis of aggressive lymphoma/leukemia based on REAL classification plus one or more of the following criteria: LDH>2xULN (IU/I), Stage III-IV disease or Stage I-III disease with at least one lymph node/tumor >5 cm.

Visit www.elitek.com for more information about Elitek(R).

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    Contact: Noelle Boyd, sanofi-aventis U.S., (908) 981-6489


'/>"/>
SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
5. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
6. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
7. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
8. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
11. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology:
(Date:5/6/2016)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) , ... May ... ... continues to earn accolades for his success in changing the way the pharmaceutical industry ... Power 100 list of the world’s most influential people in pharma, and he was ...
(Date:5/6/2016)... Chandler, AZ (PRWEB) , ... May 06, 2016 ... ... No Greater Odds, are scheduled to provide a unique keynote address at the ... documentary follows the inspirational stories of five community college students. Their stories—of complicated ...
(Date:5/6/2016)... ... ... A wide variety of national pet product manufacturers, companies and brands will gather for one ... 18 from noon to 8 p.m. at New York City’s Roger Smith Hotel. The event ... garden, outdoor and safety pet products in today’s marketplace. , Petrend Event showcases ...
(Date:5/6/2016)... Jupiter, FL (PRWEB) , ... May 06, 2016 ... ... it will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via ... with the vision of becoming a leader in optimized drug discovery through innovative ...
(Date:5/6/2016)... Pass, OR (PRWEB) , ... May 06, 2016 , ... ... eyes. In other seasons, when the weather is too cold, dry or hot, water ... the eyes can actually absorb moisture from the surrounding air. There’s only one problem, ...
Breaking Medicine News(10 mins):